Michael Sitzman

Michael Sitzman is a member of the firm's Intellectual Property and Life Science Practice Groups.  Mr. Sitzman has extensive litigation experience in the pharmaceutical and biotechnology fields; he has handled many high-profile cases for Johnson & Johnson, Novo Nordisk, Merck Serono, Alza and Medicis.  Mr. Sitzman represents brand-name pharmaceutical companies in ANDA litigation and advising on all facets of the Hatch-Waxman Act.  Mr. Sitzman was the chief architect of the litigation strategy for Novo Nordisk that culminated in the Supreme Court’s first case involving a substantive provision of the Hatch-Waxman Act.  Mr. Sitzman also represents a broad array of biotechnology companies in high stakes patent litigation involving recombinant DNA technology, antisense technology, protein synthesis and regulation, and immunological markers.
 
Mr. Sitzman received a Bachelor of Science degree from the University of California at Davis in the field of molecular genetics.  Before becoming an attorney, he worked at the U.C. Davis plant genetics laboratory and Biogenex Labs, combining the fields of immunology, histology and general chemistry.  Mr. Sitzman earned his Juris Doctor, with distinction, from University of the Pacific in 1991, where he was elected Order of the Coif.

Mr. Sitzman is a member of the State Bar of California and is registered to practice before the United States Patent and Trademark Office.  He is admitted to all Federal and State courts in California , the United States Court of Appeals for the Federal Circuit and the United States Supreme Court.  Mr. Sitzman regularly appears pro hac vice in the District Courts of New Jersey, Delaware, Maryland and the Southern District of New York.  Mr. Sitzman is also an active member of the Federal Circuit Bar Association and speaks regularly at PLI and ACI conferences on issues of biotechnology and pharmaceutical patent law.

Select Representative Matters